Why do we need noncommercial, investigator-initiated clinical trials?

Nature Clinical Practice Rheumatology

Volumn 4, Issue 7, 2008, Pages 354-355

  Tyndall, Alan ^a  

^a UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE;

ARTICLE; CLINICAL RESEARCH; CLINICAL TRIAL; COMMERCIAL PHENOMENA; DERMATOMYOSITIS; DRUG EFFICACY; FINANCIAL MANAGEMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LEGAL ASPECT; MEDICAL SOCIETY; METHODOLOGY; OFF LABEL DRUG USE; POLICY; PRIORITY JOURNAL; RESEARCH ETHICS; RHEUMATOLOGY;

CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; ETHICS, RESEARCH; EUROPE; HUMANS; RESEARCH PERSONNEL; RESEARCH SUPPORT AS TOPIC;

EID: 47149108018     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0814     Document Type: Article

References (9)

1. Choy EH et al. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Of Systematic Reviews 2005, Issue 3. Art. No.: CD003643. doi:10.1002/ 14651858.CD003643.pub2
2. The European Parliament and the Council of the European Union (2001) Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Official Journal of the European Communities L121: 34-44
3. Markman JR and Markman M (2007) Running an ethical trial 60 years after the Nuremberg Code. Lancet Oncol 8: 1139-1146
4. Goodyear MD et al. (2007) The Declaration of Helsinki. BMJ 335: 624-625
5. Carlson RV et al. (2004) The revision of the Declaration of Helsinki: Past, present and future. Br J Clin Pharmacol 57: 695-713
6. Kelleher F (2004) The pharmaceutical industry's responsibility for pi- (ecting human subjects of clinical trials in developing nations. Columbia J Law Soc Probl 38: 67-106
7. Edwards JC and Cambridge G (2001) Sustained improvement in rheumatoid arthritis following a protocol designed to daplete B lymphocytes. Rheumatology (Oxford) 40: 205-211
8. Wagner-Bohn A et al. (2007) Implementeng Good Clinical Practice in two noncommercial phase II studies in children vith cancer. Onkologie 30: 21-26
9. Halpern SD et al. (2002) The continuing unethical conduct of underpowered clinical trials. JAMA 288: 358-362